Expression and clinical significance of p53, JunB and KAI1/CD82 in human hepatocellular carcinoma
Cheng Guo1, Qing-Guang Liu, Lei Zhang
1Department of Hepatobiliary Surgery, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an 710061, China.
Background:
The mechanism of regulation of KAI1, a specific tumor metastasis suppression gene, is controversial. A recent study showed that the synergism of wild-type p53 and JunB has the function of regulating the expression of KAI1, a metastasis inhibiting factor in prostate cancer cells. The wild-type p53 gene is an activator of apoptosis and is closely related to malignant tumor cell multiplication. JunB, a member of the fos/jun family, is a key component of activator protein transcription factor and a major target element in the transmission pathway of mitosis. This study aimed to evaluate the relationship between the expression of KAI1 and p53 combined with JunB in tumor tissues and clinical outcomes in hepatocellular carcinoma (HCC) patients.
Methods:
Quantitative real-time RT-PCR, Western blotting techniques and immunohistochemistry were used to evaluate the expression of KAI1 mRNA, KAI1/CD82, p53 and JunB in HCC patients, and the relationship between their expression and the clinicopathological prognostic parameters was analyzed.
Results:
In cancer tissues, the values for positive expression of KAI1 mRNA, KAI1/CD82, p53 and JunB were 31.25%, 26.25%, 48.75%, and 20.00%, respectively, while in adjacent non-tumor tissues, they were 100%, 94.74%, 2.63%, and 76.32%, respectively. There was no correlation between the expression levels of p53 or JunB and KAI1 mRNA or KAI1/CD82. However, there were significant correlations between the expression levels of p53 combined with JunB and not only KAI1 mRNA but also KAI1/CD82 proteins.
Conclusions:
When p53 dysfunction and low expression of JunB are simultaneous, they may play an important role in down-regulating the expression of KAI1 by synergism in HCC. But further studies in vivo and in vitro are needed to verify these results.
Insights
In hepatocellular carcinoma (HCC), simultaneous p53 dysfunction and low JunB expression may down-regulate KAI1, a metastasis suppressor. Further in vivo and in vitro studies are needed to confirm this finding regarding KAI1 regulation in HCC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- KAI1 is a tumor metastasis suppressor gene with controversial regulatory mechanisms.
- Wild-type p53 and JunB synergistically regulate KAI1 expression in prostate cancer cells.
- p53 is crucial for apoptosis and tumor cell multiplication, while JunB is involved in transcription factor regulation and mitosis.
Purpose of the Study:
- To investigate the relationship between KAI1 expression and p53/JunB in hepatocellular carcinoma (HCC) tissues.
- To analyze the correlation between KAI1, p53, and JunB expression and patient outcomes in HCC.
Main Methods:
- Quantitative real-time RT-PCR and Western blotting to assess KAI1 mRNA and protein levels.
- Immunohistochemistry to evaluate p53 and JunB expression in HCC tissues.
- Statistical analysis to correlate expression levels with clinicopathological parameters.
Main Results:
- KAI1 mRNA and protein expression were significantly lower in cancer tissues compared to adjacent non-tumor tissues.
- While individual p53 or JunB expression showed no correlation with KAI1, their combined expression was significantly correlated with KAI1 mRNA and KAI1/CD82 protein levels.
- Positive expression rates for KAI1 mRNA, KAI1/CD82, p53, and JunB in cancer tissues were 31.25%, 26.25%, 48.75%, and 20.00%, respectively.
Conclusions:
- Simultaneous p53 dysfunction and low JunB expression may synergistically down-regulate KAI1 in HCC.
- These findings suggest a potential role for p53 and JunB in HCC metastasis suppression via KAI1 regulation.
- Further in vivo and in vitro studies are required to validate these results and elucidate the precise mechanisms.
Related Concept Videos
02:23Abnormal Proliferation
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...